{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:19:17Z","timestamp":1778602757162,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.abd.2024.04.012","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T20:39:34Z","timestamp":1734467974000},"page":"243-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dupilumab, corticosteroids and their combination for the treatment of bullous pemphigoid"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9414-2891","authenticated-orcid":false,"given":"Guirong","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7085-9388","authenticated-orcid":false,"given":"Hua","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4585-3344","authenticated-orcid":false,"given":"Chao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9206-7330","authenticated-orcid":false,"given":"Hanmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8560-9207","authenticated-orcid":false,"given":"Zhiliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4764-5976","authenticated-orcid":false,"given":"Suo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5374-6955","authenticated-orcid":false,"given":"Ke","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3084-4891","authenticated-orcid":false,"given":"Chenjing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4120-4873","authenticated-orcid":false,"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3211-8922","authenticated-orcid":false,"given":"Ruiyu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6419-5693","authenticated-orcid":false,"given":"Xiaoguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1045-9064","authenticated-orcid":false,"given":"Suying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2024.04.012_bib0005","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.abd.2024.04.012_bib0010","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/jdv.15679","article-title":"Review of autoimmune blistering diseases: the Pemphigoid diseases","volume":"33","author":"Daniel","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2024.04.012_bib0015","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.autrev.2017.03.010","article-title":"Bullous pemphigoid","volume":"16","author":"Ba\u011fc\u0131","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.abd.2024.04.012_bib0020","article-title":"Interventions for bullous pemphigoid","volume":"2010","author":"Kirtschig","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.abd.2024.04.012_bib0025","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1046\/j.0022-202x.2001.01505.x","article-title":"Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells","volume":"117","author":"Teraki","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.abd.2024.04.012_bib0030","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2020.03.017","article-title":"Interleukin 4 and interleukin 13 inhibition: a promising therapeutic approach in bullous pemphigoid","volume":"83","author":"Geller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.04.012_bib0035","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaad.2019.07.060","article-title":"Pathophysiologic mechanisms of itch in bullous pemphigoid","volume":"83","author":"Hashimoto","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.04.012_bib0040","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/205873929901200202","article-title":"A Th2-like cytokine response is involved in bullous pemphigoid. the role of IL-4 and IL-5 in the pathogenesis of the disease","volume":"12","author":"Feliciani","year":"1999","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.abd.2024.04.012_bib0045","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0923-1811(02)00067-1","article-title":"Th1, Th2 and Th3 cytokines in the pathogenesis of bullous pemphigoid","volume":"30","author":"Giomi","year":"2002","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.abd.2024.04.012_bib0050","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1046\/j.1365-2133.2000.03599.x","article-title":"Elevated levels of eotaxin and interleukin\u20105 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia","volume":"143","author":"Wakugawa","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2024.04.012_bib0055","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.clim.2006.03.014","article-title":"Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines","volume":"120","author":"Gounni Abdelilah","year":"2006","journal-title":"Clin Immunol"},{"key":"10.1016\/j.abd.2024.04.012_bib0060","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.abd.2024.04.012_bib0065","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13190","article-title":"Targeting interleukin 4 receptor \u03b1: a new approach to the treatment of cutaneous autoimmune bullous diseases?","volume":"33","author":"Russo","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2024.04.012_bib0070","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2024.04.012_bib0075","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.04.012_bib0080","doi-asserted-by":"crossref","DOI":"10.5070\/D32511046147","article-title":"Dupilumab for bullous pemphigoid with intractable pruritus","volume":"25","author":"Seidman","year":"2019","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.abd.2024.04.012_bib0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.611549","article-title":"Case report: combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid","volume":"11","author":"Seyed Jafari","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.abd.2024.04.012_bib0090","doi-asserted-by":"crossref","DOI":"10.5070\/D3274053155","article-title":"Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature","volume":"27","author":"Saleh","year":"2021","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.abd.2024.04.012_bib0095","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/ajd.13692","article-title":"Dupilumab successfully treated refractory bullous pemphigoid with early clinical manifestations imitating atopic dermatitis: a case letter","volume":"62","author":"Zhang","year":"2021","journal-title":"Australas J Dermatol"},{"issue":"9","key":"10.1016\/j.abd.2024.04.012_bib0100","doi-asserted-by":"crossref","DOI":"10.5070\/D327955136","article-title":"Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature","volume":"27","author":"Klepper","year":"2021","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.abd.2024.04.012_bib0105","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15727","article-title":"Severe pemphigoid nodularis successfully treated with dupilumab","volume":"35","author":"Jendoubi","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2024.04.012_bib0110","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jdcr.2021.09.014","article-title":"Nonbullous erythrodermic pemphigoid with florid lymphadenopathy, response to dupilumab","volume":"17","author":"Bal","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.abd.2024.04.012_bib0115","article-title":"Efficacy and safety of dupilumab in moderate-to-severe Bullous Pemphigoid","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.abd.2024.04.012_bib0120","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of dupilumab in patients with Bullous Pemphigoid","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2024.04.012_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110050","article-title":"The efficacy and safety of dupilumab combined with methylprednisolone in the treatment of bullous pemphigoid in China","volume":"118","author":"Qi","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.abd.2024.04.012_bib0130","doi-asserted-by":"crossref","first-page":"e539","DOI":"10.1111\/jdv.17999","article-title":"Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real-life study","volume":"36","author":"Velin","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2024.04.012_bib0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1194088","article-title":"Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types","volume":"14","author":"Yan","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.abd.2024.04.012_bib0140","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15648","article-title":"Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid","volume":"35","author":"Yang","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2024.04.012_bib0145","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.abd.2024.04.012_bib0150","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.04.012_bib0155","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s00403-023-02639-w","article-title":"Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are positively correlated with disease activity of bullous pemphigoid","volume":"315","author":"Sun","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.abd.2024.04.012_bib0160","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1097\/CM9.0000000000002196","article-title":"Diagnostic values of indirect immunofluorescence using salt-split skin, direct immunofluorescence and BP180 NC16A ELIS.A on bullous pemphigoid","volume":"135","author":"Li","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.abd.2024.04.012_bib0165","series-title":"R: a language and environment for statistical computing","year":"2022"},{"key":"10.1016\/j.abd.2024.04.012_bib0170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.912876","article-title":"Insights into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms","volume":"13","author":"Cole","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.abd.2024.04.012_bib0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102661","article-title":"The role of T cells in pemphigus vulgaris and bullous pemphigoid","volume":"19","author":"Fang","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.abd.2024.04.012_bib0180","doi-asserted-by":"crossref","first-page":"368","DOI":"10.23736\/S0031-0808.20.03997-X","article-title":"Eosinophils in bullous pemphigoid","volume":"63","author":"Jones","year":"2021","journal-title":"Panminerva Med"},{"key":"10.1016\/j.abd.2024.04.012_bib0185","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.jaci.2018.03.014","article-title":"Regulatory T-cell dysfunction induces autoantibodies to bullous pemphigoid antigens in mice and human subjects","volume":"142","author":"Muramatsu","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.abd.2024.04.012_bib0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00403-017-1789-1","article-title":"IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review","volume":"310","author":"Saniklidou","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.abd.2024.04.012_bib0195","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2340\/00015555-2101","article-title":"Enzyme-linked immunoassay index for Anti-NC16a IgG and IgE auto-antibodies correlates with severity and activity of bullous pemphigoid","volume":"96","author":"Kalowska","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.abd.2024.04.012_bib0200","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0190-9622(87)80227-X","article-title":"Blood eosinophilia as a severity marker for bullous pemphigoid","volume":"16","author":"Bernard","year":"1987","journal-title":"J Am Acad Dermatol"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059624002496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059624002496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:00:52Z","timestamp":1747666852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059624002496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0365059624002496"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2024.04.012","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab, corticosteroids and their combination for the treatment of bullous pemphigoid","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2024.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}